Integrating New Treatments for HER2+ Early Breast Cancer
Symposium
Symposium

Integrating New Treatments for HER2+ Early Breast Cancer

Time for a Risk-Adapted Approach

Not a member of My prIME? Join now for instant access.

Meeting Overview

Enhance your understanding of optimal treatment approaches for HER2+ early breast cancer at this interactive satellite symposium. A variety of therapeutic strategies will be discussed, including short duration regimens, extended adjuvant therapy, dual HER2 blockade, and patient selection for these strategies. Optimizing the risk-benefit profile of different regimens will also be addressed, with information on prevention and management of adverse events. Finally, emerging agents and potential future opportunities provided by new HER2-targeted strategies that address areas of continuing unmet clinical need will be covered. Attendees will have the opportunity to interact with the expert faculty throughout the symposium.

Date and Location

Monday, 11 September 2017
18.30 – 20.00

Valencia Auditorium, Hall 4
IFEMA – Feria de Madrid
Madrid, Spain

Date/Time

Date/Time

Monday, 11 September 2017
18.30 – 20.00

Location

Location

Madrid, Spain

IME

IME

18.30 Welcome and introduction
Hope S. Rugo, MD, FACP
18.32 The spectrum of HER2+ early breast cancer: Clinical scenarios and treatment recommendations
Hope S. Rugo, MD, FACP
18.40 The case for dual blockade
Sibylle Loibl, MD, PhD 
18.50 The case for extended adjuvant treatment
Michael Untch, MD, PhD
19.00 The case for reduced treatment
Thomas Bachelot, MD, PhD
19.10 Optimizing the risks and benefits of treatment
Wolfgang Janni, MD, PhD
19.20 Borrowing from Maria to treat Sophia: A risk-adapted approach to treatment
Suzette Delaloge, MD, MSc
19.30 Emerging treatments for HER2+ and mutant breast cancer
Cristina Saura, MD, PhD
19.40 Panel discussion
Hope S. Rugo, MD, FACP, and Faculty
19.50 Decision time: Opportunity to reflect on treatment recommendations
Hope S. Rugo, MD, FACP
19.58 prIME Points™
Hope S. Rugo, MD, FACP
20.00 Adjourn

    Chair

  • Hope S. Rugo, MD, FASCOUniversity of California, San Francisco
    Helen Diller Family Comprehensive Cancer Center
    San Francisco, California, United States
  • Faculty

  • Thomas Bachelot, MD, PhDCentre Léon Bérard
    Lyon, France
  • Suzette Delaloge, MD, MScGustave Roussy
    Villejuif, France
  • Wolfgang Janni, MD, PhDUniversity of Ulm
    Ulm, Germany
  • Sibylle Loibl, MD, PhDGerman Breast Group, Neu-Isenburg
    Centre for Haematology and Oncology Bethanien
    Frankfurt, Germany
  • Cristina Saura, MD, PhDVall d’Hebron University Hospital
    Barcelona, Spain
  • Michael Untch, MD, PhDHELIOS Klinikum Berlin-Buch
    Berlin, Germany

This educational activity is specifically designed for oncologists and other healthcare professionals interested in and/or involved in the treatment of breast cancer that wish to understand some of the latest developments in treatments for patients with HER2+ breast cancer.

After successful completion of this educational activity, participants should be able to:

  • Evaluate the results of recent clinical trials in HER2+ early breast cancer that explore the evolution of adjuvant treatment strategies
  • Select the optimum HER2-targeted strategy and duration of treatment to improve long-term disease endpoints in patients with HER2+ early breast cancer
  • Identify supportive care interventions to minimize adverse events with HER2-targeted therapy
  • Understand the limitations of health care funding for HER2+ early breast cancer and the need for a risk-adapted strategy

This educational activity is supported by a grant from Puma Biotechnology.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

Provider

This activity is provided by prIME Oncology.

SUNSHINE ACT/EFPIA DISCLOSURE STATEMENT

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.

Disclosures

Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.